Acetyl octapeptide-3 (SNAP-8)
Also known as: SNAP-8, Acetyl octapeptide-3, Acetyl-glu-glu-met-gln-arg-arg-ala-asp-amide
Overview
Acetyl octapeptide-3—often marketed as SNAP-8—is a synthetic cosmetic peptide used in topical formulations aimed at reducing the appearance of expression lines. It is commonly described as an 'Argireline-like' peptide in marketing materials, but it is a distinct sequence and should be treated as a cosmetic ingredient rather than a therapeutic peptide. In the peptide marketplace, SNAP-8 sometimes gets grouped with injectable or systemic 'wellness' peptides, yet its mainstream use case is topical skincare. That matters for risk interpretation: topical cosmetic use does not imply systemic bioavailability, and systemic claims would require entirely different evidence. For reference purposes, the most reliable public identifiers come from chemical registries (CAS, PubChem), which list synonyms and composition details used by suppliers and formulators.
Mechanism of Action
Often described as a peptide intended to modulate neuromuscular signaling related to expression lines; independent clinical mechanism validation is limited and many claims are marketing-driven. Treat as a topical cosmetic ingredient unless evidence supports otherwise.
Potential Benefits
- Marketed as a topical ingredient for reducing the appearance of expression lines.
- Used in cosmetic formulations alongside other peptides such as Matrixyl and Argireline.
- Generally stable in topical aqueous formulations.
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
Consult published research literature for study-specific protocols.
Routes of Administration
Topical Limited; cosmetic surface-level use.
Systemic absorption is not the expected route.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Reconstitution
| Storage | Per product label |
|---|
Need exact syringe measurements?
Amino Acid Sequence
Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2
Side Effects & Safety
- Topical irritation possible in sensitive skin types.
- Allergic contact dermatitis reported rarely with peptide-containing serums.
- Systemic effects not characterized.
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Known peptide allergy
Patch test recommended for sensitive skin.
Drug Interactions
- Other topical cosmetic actives: Formulation-dependent; topical irritants combined with peptide serums may increase irritation potential.
Pharmacokinetics
| Half-Life | Not characterized for topical cosmetic ingredients in the same way as systemic peptide drugs. |
|---|---|
| Storage | Per cosmetic formulation supplier guidance. |
Synergistic Compounds
The following compounds have been studied alongside Acetyl octapeptide-3 (SNAP-8) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.
MetaVia's DA-1726 posts -9.1% Phase 1 weight loss and FibroScan signals at EASL Congress 2026
MetaVia's DA-1726 Phase 1 readout at EASL 2026 showed -9.1% body weight at Day 54 and directional liver-fat improvement in the 48 mg cohort, no plateau.
Alabama medical board bans research-grade peptide prescribing, closes consent-form workaround
Alabama's medical board on May 26 prohibited physicians from prescribing, compounding, or administering any non-FDA-approved peptide, with no consent-form exception.